Zymeworks Common Stock Stock EBITDA
| ZYME Stock | USD 14.09 0.33 2.29% |
Zymeworks Common Stock fundamentals help investors to digest information that contributes to Zymeworks Common's financial success or failures. It also enables traders to predict the movement of Zymeworks Stock. The fundamental analysis module provides a way to measure Zymeworks Common's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Zymeworks Common stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -130 M | -123.5 M |
Zymeworks | EBITDA |
Zymeworks Common Stock Company EBITDA Analysis
Zymeworks Common's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Zymeworks Common EBITDA | (129.96 M) |
Most of Zymeworks Common's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zymeworks Common Stock is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Zymeworks EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Zymeworks Common is extremely important. It helps to project a fair market value of Zymeworks Stock properly, considering its historical fundamentals such as EBITDA. Since Zymeworks Common's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Zymeworks Common's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Zymeworks Common's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Zymeworks Ebitda
Ebitda |
|
According to the company disclosure, Zymeworks Common Stock reported earnings before interest,tax, depreciation and amortization of (129.96 Million). This is 114.81% lower than that of the Biotechnology sector and 229.75% lower than that of the Health Care industry. The ebitda for all United States stocks is 103.33% higher than that of the company.
Zymeworks EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zymeworks Common's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Zymeworks Common could also be used in its relative valuation, which is a method of valuing Zymeworks Common by comparing valuation metrics of similar companies.Zymeworks Common is currently under evaluation in ebitda category among its peers.
Zymeworks Common Current Valuation Drivers
We derive many important indicators used in calculating different scores of Zymeworks Common from analyzing Zymeworks Common's financial statements. These drivers represent accounts that assess Zymeworks Common's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Zymeworks Common's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.7B | 2.4B | 1.1B | 512.4M | 715.5M | 800.3M | |
| Enterprise Value | 1.6B | 2.1B | 910.5M | 139.6M | 584.7M | 673.9M |
Zymeworks Common ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Zymeworks Common's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Zymeworks Common's managers, analysts, and investors.Environmental | Governance | Social |
Zymeworks Common Institutional Holders
Institutional Holdings refers to the ownership stake in Zymeworks Common that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Zymeworks Common's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Zymeworks Common's value.| Shares | Farallon Capital Management, L.l.c. | 2024-09-30 | 1.4 M | State Street Corp | 2024-09-30 | 1.2 M | Nextech Invest Ag | 2024-09-30 | 1.1 M | Tang Capital Management Llc | 2024-09-30 | 1.1 M | Samsara Biocapital, Llc | 2024-09-30 | 1000 K | Prosight Management, Lp | 2024-09-30 | 917.6 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 849.5 K | Bridgeway Capital Management, Llc | 2024-09-30 | 742.6 K | Geode Capital Management, Llc | 2024-09-30 | 713.9 K | Ecor1 Capital, Llc | 2024-09-30 | 13.4 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 5.1 M |
Zymeworks Fundamentals
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (1.83) % | ||||
| Operating Margin | (2.14) % | ||||
| Current Valuation | 693.53 M | ||||
| Shares Outstanding | 68.88 M | ||||
| Shares Owned By Insiders | 0.08 % | ||||
| Shares Owned By Institutions | 98.89 % | ||||
| Number Of Shares Shorted | 4.21 M | ||||
| Price To Earning | (2.36) X | ||||
| Price To Book | 2.64 X | ||||
| Price To Sales | 15.97 X | ||||
| Revenue | 76.01 M | ||||
| Gross Profit | 203.78 M | ||||
| EBITDA | (129.96 M) | ||||
| Net Income | (118.67 M) | ||||
| Cash And Equivalents | 241.83 M | ||||
| Cash Per Share | 4.18 X | ||||
| Total Debt | 26.72 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 3.29 X | ||||
| Book Value Per Share | 5.27 X | ||||
| Cash Flow From Operations | (118.3 M) | ||||
| Short Ratio | 7.54 X | ||||
| Earnings Per Share | (1.49) X | ||||
| Target Price | 17.86 | ||||
| Number Of Employees | 294 | ||||
| Beta | 1.16 | ||||
| Market Capitalization | 993.21 M | ||||
| Total Asset | 580.88 M | ||||
| Retained Earnings | (677.44 M) | ||||
| Working Capital | 357.16 M | ||||
| Net Asset | 580.88 M |
About Zymeworks Common Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zymeworks Common Stock's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zymeworks Common using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zymeworks Common Stock based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zymeworks Common Stock is a strong investment it is important to analyze Zymeworks Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zymeworks Common's future performance. For an informed investment choice regarding Zymeworks Stock, refer to the following important reports:Check out Zymeworks Common Piotroski F Score and Zymeworks Common Altman Z Score analysis. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zymeworks Common. If investors know Zymeworks will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zymeworks Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.49) | Revenue Per Share 0.831 | Quarterly Revenue Growth (0.03) | Return On Assets (0.15) | Return On Equity (0.29) |
The market value of Zymeworks Common Stock is measured differently than its book value, which is the value of Zymeworks that is recorded on the company's balance sheet. Investors also form their own opinion of Zymeworks Common's value that differs from its market value or its book value, called intrinsic value, which is Zymeworks Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zymeworks Common's market value can be influenced by many factors that don't directly affect Zymeworks Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zymeworks Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zymeworks Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zymeworks Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.